TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: guidance

This guidance is a review and extension of Technology Appraisal Guidance No. 14 issued in October 2000. The Institute reviews each piece of guidance it issues.

The review and re-appraisal has resulted in an extension to the guidance; combination therapy with pegylated interferon alfa and ribavirin is recommended for the treatment of people aged 18 years and over with moderate to severe chronic hepatitis C.